Methods and compositions for cell-proliferation-related disorders

Abstract

Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).

1 - 6 . (canceled) 
     
     
         7 . A method of diagnosing a subject having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder characterized by:
 (a) the presence, distribution, or level of an isocitrate dehydrogenase 2 enzyme having a mutation at residue 140 wherein the arginine residue has been replaced with a glutamine residue (IDH2-R140Q), which has 2HG (2-hydroxyglutarate) neoactivity, wherein 2HG neoactivity is the ability to convert alpha ketoglutarate to 2-hydroxyglutarate; or   (b) elevated levels of 2HG due to the presence of an IDH2-R140Q mutant enzyme having 2HG neoactivity,   wherein said method comprises analyzing the presence, distribution, or level of 2HG in a tissue, product, or bodily fluid of said subject by a chromatographic method, wherein an increased presence, distribution, or level of 2HG indicates the presence of the cell proliferation-related disorder, thereby diagnosing the subject for the cell proliferation-related disorder.   
     
     
         8 . (canceled) 
     
     
         9 . The method of  claim 7  wherein said cell proliferation-related disorder is selected from the group consisting of acute lymphoblastic leukemia and acute myelogenous leukemia. 
     
     
         10 . The method of  claim 7 , wherein said bodily fluid is blood, plasma, or urine. 
     
     
         11 . The method of  claim 7 , wherein the chromatographic method is LC-MS. 
     
     
         12 . The method of  claim 7 , wherein the chromatographic method is GC-MS. 
     
     
         13 - 18 . (canceled)